GS-444217

Also Known As:

4-(4-cyclopropyl-1H-imidazol-1-yl)-N-(3-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)phenyl)picolinamide; 4-(4-cyclopropylimidazol-1-yl)-N-(3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl)pyridine-2-carboxamide; Ask1-IN-1

Networked: 7 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - GS-444217: 7
  - Pyridines: 88
    - GS-444217: 7

Experts

1.	Liles, John T: 4 articles (10/2018 - 11/2015)
2.	Breckenridge, David G: 3 articles (10/2018 - 11/2015)
3.	Ma, Frank Y: 3 articles (10/2018 - 11/2015)
4.	Nikolic-Paterson, David J: 3 articles (10/2018 - 11/2015)
5.	Budas, Grant R: 2 articles (10/2018 - 01/2018)
6.	Hinojosa-Kirschenbaum, Ford: 2 articles (10/2018 - 01/2018)
7.	Han, Yingjie: 2 articles (01/2018 - 11/2015)
8.	Tesch, Greg H: 2 articles (01/2018 - 11/2015)
9.	Fu, Guoquan: 1 article (06/2022)
10.	Gao, Yue: 1 article (06/2022)

Related Diseases

1.	Fibrosis (Cirrhosis) 01/01/2018 - "Importantly, efficacy was observed when GS-444217 was administered to animals with established disease and also directly reduced cardiac fibrosis and improved cardiac function in a model of isolated RV pressure overload. " 10/01/2018 - "We describe the discovery and characterization of a potent and selective small-molecule inhibitor of ASK1, GS-444217, and demonstrate the therapeutic potential of ASK1 inhibition to reduce kidney injury and fibrosis. " 01/01/2018 - "Macrophage activation, T-cell infiltration and renal fibrosis were also reduced by GS-444217. " 01/01/2021 - "GS-444217 attenuated the development of GS, podocyte loss, tubular injury, interstitial inflammation and renal fibrosis in Tg26 mice. " 10/01/2018 - "Treatment with GS-444217 reduced progressive inflammation and fibrosis in the kidney and halted glomerular filtration rate decline. "
2.	Inflammation (Inflammations) 11/01/2015 - "Late intervention with GS-444217 improved renal function and halted the progression of glomerulosclerosis, renal inflammation, and tubular injury despite having no effect on established albuminuria. " 01/01/2021 - "GS-444217 attenuated the development of GS, podocyte loss, tubular injury, interstitial inflammation and renal fibrosis in Tg26 mice. " 10/01/2018 - "Treatment with GS-444217 reduced progressive inflammation and fibrosis in the kidney and halted glomerular filtration rate decline. "
3.	Albuminuria 11/01/2015 - "Late intervention with GS-444217 improved renal function and halted the progression of glomerulosclerosis, renal inflammation, and tubular injury despite having no effect on established albuminuria. " 11/01/2015 - "Early intervention with GS-444217 significantly inhibited diabetic glomerulosclerosis and reduced renal dysfunction but had no effect on the development of albuminuria. "
4.	Disease Progression 01/01/2021 - "Recent studies have highlighted the role of apoptosis signal-regulating kinase 1 (ASK1) in driving kidney disease progression through the activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase and selective ASK-1 inhibitor GS-444217 was recently shown to reduce kidney injury and disease progression in various experimental models. "
5.	Kidney Diseases (Kidney Disease) 01/01/2021 - "Recent studies have highlighted the role of apoptosis signal-regulating kinase 1 (ASK1) in driving kidney disease progression through the activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase and selective ASK-1 inhibitor GS-444217 was recently shown to reduce kidney injury and disease progression in various experimental models. "

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	MAP Kinase Kinase Kinase 5
3.	JNK Mitogen-Activated Protein Kinases
4.	Monocrotaline
5.	Enalapril
6.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
7.	chromium hexavalent ion

Related Therapies and Procedures

1.	Oral Administration